expected to form a complex with human FH. In human FH transgenic mice, binding of FH to FHbp decreased serum bactericidal antibody responses [11] [12] [13] . Immunized humans develop complement-mediated serum bactericidal antibody responses [14] [15] [16] , but little is known about the effect of FH binding to the vaccine antigen on the human anti-FHbp antibody repertoire or antibody functional activity. This question has been difficult to address in clinical trials because FH binding is specific for human FH [10] and because, to date, all of the FHbp vaccines tested in humans bound human FH. In the present study, we investigated the effect of FH binding on the immunogenicity of the U.S.-and European-licensed 4CMenB in a nonhuman primate model. Because of an amino acid polymorphism in FH domain 6, there is heterogeneity in macaque FH binding to FHbp [17] . Therefore, some immunized animals had low FH binding to the FHbp vaccine antigen, while others had high binding with similar affinity as human FH.
MATERIALS AND METHODS

Rhesus Macaques
The animals were born and housed at the California National Primate Research Center (Davis) in accordance with American Association for Accreditation of Laboratory Animal Care standards. They were maintained in outdoor social housing with their dams and extended families. The colony's founders and genetic relationships [18, 19] and the presence of a FH polymorphism associated with strong or weak FH binding to FHbp have been described elsewhere [17] . We strictly adhered to the Guide for the Care and Use of Laboratory Animals [20] . The study was approved by the Institutional Animal Care and Use Committee of the University of California-Davis.
At ages 2-3 months, we screened sera from 25 animals for binding of macaque FH to FHbp ID 1 by enzyme-linked immunosorbent assay (ELISA), as previously described [17] . Six animals with strong binding (FHbp-FH high ) and 6 with weak FH binding (FHbp-FH low ) were selected for vaccination. An additional monkey with FHbp-FH high and 2 with FHbp-FH low were followed as negative unvaccinated controls. The respective macaque FH-binding phenotypes were confirmed by a flow cytometric assay with live meningococci.
Immunogenicity
A human 4CMenB dose (0.5 mL) contains 50 µg each of 3 recombinant proteins, which are combined with 25 µg of detergent-treated outer-membrane vesicles [6, 21] . The 4 components are adsorbed with aluminum hydroxide (0.5 mg Al
3+
per human dose) [14, 22] . At ages 3-4 months, the animals were vaccinated intramuscularly with 1 human dose divided into two 0.25-mL aliquots, which were given as separate injections in each leg. A second dose was given 1 month later. Blood samples were obtained 3 weeks after the second dose.
Serum IgG Anti-FHbp Antibody Responses
Serum IgG anti-FHbp titers were measured by ELISA, using recombinant FHbp ID 1 as the antigen on the plate [23] . Bound immunoglobulin G (IgG) was measured by alkaline phosphatase-conjugated goat anti-human IgG (Fc specific; Sigma), which cross-reacts with macaque IgG.
Neisseria meningitidis
We measured serum bactericidal antibody responses against 3 invasive serogroup B meningococcal strains: H44/76, 5/99, and SK016. These strains have been previously used in 4CMenB immunogenicity studies to measure antigen-specific serum bactericidal antibody responses to FHbp [14, 22] , NadA [14, 22] , and PorA P1.4 [12] , respectively. Each strain was mismatched for the other 4CMenB antigens known to elicit bactericidal antibody and was killed by human complement only with a mouse antiserum to the matched antigen [12] . We also tested serum anti-FHbp bactericidal antibody responses against 4 mutants of strain H44/76 in which the gene encoding the native FHbp ID 1 that matched the FHbp antigen in 4CMenB had been replaced by either FHbp ID 4, 13, or 15 (subfamily B) or by FHbp ID 22 (subfamily A). The H44/76 mutants were prepared and characterized as previously described for similar mutants from strain NZ98/254 [24] .
Bactericidal Assay
Bacteria were grown to mid-log phase in Franz medium supplemented with 4 mM D,L-Lactate (Sigma) and 2 mM cytidine 5′-monophospho-N-acetyl-neuraminic acid (Carbosynth) to enhance sialylation of lipooligosaccharide [25] . Test sera were heated for 30 minutes at 56°C to inactivate complement. The exogenous human complement underwent human serum depletion of IgG with a protein G column (HiTrap Protein G HP 1 mL; GE Healthcare) [11] . Serum titers were assigned by the dilution resulting in 50% survival of the bacteria, compared with the density of bacteria incubated for 60 minutes with negative control sera and complement.
Flow Cytometry With Live N. meningitidis for Detection of Bound FH
The assay was performed as previously described [12, 26] . In brief, 10 7 colony-forming units (CFU)/mL of bacteria were in- C4b Deposition on N. meningitidis
We performed flow cytometry to measure deposition of human C4b on the surface of live meningococci, as previously described [27] . In brief, bacteria were grown as described above and resuspended in D-PBS-BSA to a density of approximately 10 8 CFU/mL.
The bacteria were incubated with human complement (5% IgGdepleted human serum) and a 1:40 dilution of macaque sera. After incubation for 15 minutes at room temperature, bound human C4b was detected with a 1:100 dilution of fluorescein isothiocyanate-conjugated anti-human C4b (Meridian Life Science).
Statistical Analyses
For calculation of geometric mean titers (GMTs), titers below the limit of the detection were assigned half the value of the lowest dilution tested. The Student t test or, where appropriate, the Mann-Whitney U test was used to compare the geometric means between 2 independent test samples. All statistical tests were 2-tailed; P values of ≤.05 were considered statistically significant.
RESULTS
Selection of Macaques
Six animals with FHbp-FH high and 6 with FHbp-FH low were selected for vaccination. An additional macaque with FHbp-FH high and 2 with FHbp-FH low were followed as negative unvaccinated controls. The mean binding of FH to FHbp by ELISA in the 2 groups is shown in Figure 1A . Serum FHbp-FH high or FHbp- We tested serum bactericidal titers against 3 invasive serogroup B strains, each with only 1 antigen that matched one of the 4 antigens in 4CMenB that are known to elicit serum bactericidal activity [6] . Against strain SK016, which is susceptible to antibodies elicited by PorA subtype P1.4 in the outermembrane vesicle component [12] , and strain 5/99, which is susceptible to antibodies elicited by the recombinant NadA antigen [14, 22] , the respective serum bactericidal titers of the macaques with FHbp-FH high or FHbp-FH low phenotype were not significantly different from each other (P > .2; Figure 2B and 2C). Against strain H44/76, which is susceptible to antibodies to the recombinant FHbp antigen [14, 22] , there was a trend for lower serum bactericidal antibody responses in the macaques with FHbp-FH high (reciprocal GMT, 226 vs 394 in macaques with the FHbp-FH low phenotype; P = .08; Figure 2D ). The FHbp sequence variant, ID 1, in strain H44/76 matches the FHbp ID 1 antigen in 4CMenB. We also tested serum antiFHbp bactericidal antibody responses against 4 H44/76 mutants in which the gene encoding FHbp ID 1 had been replaced by either FHbp ID 4, 13, or 15 (subfamily B, with 87%-96% amino acid identity, compared with ID 1), or FHbp ID 22 (subfamily A, with 69% amino acid identity to ID 1; Figure 3A ). For all 4 mutants, expression of FHbp was similar to that of the parent wild-type H44/76 strain ( Figure 3B ), which is known to express relatively high levels of FHbp [30] .
Against the 4 mutants, the respective reciprocal serum bactericidal GMTs of the macaques with the FHbp-FH high phenotype were significantly lower than those of the macaques with FHbp-FH low (P ≤ .005 for each comparison; Figure 3C ; titers of the individual animals in each group against each of the mutants are shown in Supplementary Figure 1) . In both groups of macaques, there were decreasing serum bactericidal titers with increasing sequence divergence between the FHbp ID 1 in the vaccine and FHbp antigen in the mutant strain ( Figure 3A and 3C). This result was expected on the basis of previous data from wild-type mice immunized with different recombinant FHbp vaccines [24] . 
Postimmunization Sera From Macaques That Received 4CMenB Enhance Binding of FH to Meningococci
In previous studies, the serum anti-FHbp antibodies of 4CMenB-vaccinated wild-type mice whose FH did not bind to the FHbp vaccine antigen-inhibited binding of human FH to FHbp, which increased bactericidal activity [12, 24] . We therefore investigated the ability of postimmunization macaque sera to inhibit binding of macaque FH to the wild-type H44/76 strain ( Figure 4) . The macaque sera were tested at a 1:150 dilution and served as a source of both antibody and macaque FH. The postimmunization sera from vaccinated macaques with the FHbp-FH high or FHbp-FH low phenotypes enhanced macaque FH binding, compared with the respective preimmunization sera ( Figure 4A ). There were no changes in serum FH binding between 2 and 3 months of age and 5 and 6 months of age in negative control macaques that had not been vaccinated (Figure 4A ). When the data from all 12 vaccinated macaques were analyzed, there were significant increases in binding of macaque serum FH after vaccination in both groups (P ≤ .002, by the Mann-Whitney U test; Figure 4B ). In contrast, when a serum pool from wild-type mice immunized with 4CMenB was added as a source of antibody to negative control serum from a nonvaccinated macaque (as a source of macaque FHbp-FH high ), there was complete inhibition of macaque FH binding ( Figure 4C ). We also investigated the effect of the postimmunization macaque sera on binding of human FH to meningococci and found similar enhancement to that found with binding of macaque FH to the bacteria (Supplementary Figure 2) . As expected [12, 24] , the sera from control wildtype mice that received 4CMenB inhibited binding of human FH (Supplementary Figure 2C) . Deposition of human C4b on the surface of live N. meningitidis cells can be used as a marker of lectin and/or classical complement pathway activation [27] . As shown in Figure 5A , there was significantly less C4b deposition elicited by a postimmunization serum sample from a macaque with the FHbp-FH high phenotype than a macaque with the FHbp-FH low phenotype. The geometric mean of the median fluorescence intensity for the 6 macaques with the FHbp-FH high phenotype was 4-fold lower than that of the macaques with the FHbp FH low phenotype (P = .007; Figure 5B ). Collectively, these data indicate that the lower serum anti-FHbp bactericidal titers of the macaques with the FHbp-FH high phenotype resulted at least in part from less activation of the classical pathway.
DISCUSSION
In previous studies, immunization of wild-type mice with different FHbp vaccines elicited serum anti-FHbp antibodies that activated the classical complement pathway directly and also inhibited binding of FH to the bacteria [4, 26, 30] . With less bound FH, the bacteria became more susceptible to . The dotted line represents FH binding with the macaque serum tested without added mouse antiserum. In contrast to the sera from macaques that received 4CMenB, the mouse antiserum to 4CMenB showed nearly complete inhibition of binding of macaque FH to the bacteria. complement-mediated killing by the alternative pathway. This dual antibody function was especially important for eliciting bactericidal activity against meningococcal strains with low expression of FHbp [26, 30] or with FHbp amino acid sequences that did not closely match that of the vaccine antigen [24] .
In immunized humans, the FHbp vaccine antigen is expected to form a complex with human FH. Data from a human FH transgenic mouse model indicated that the presence of human FH skewed the serum anti-FHbp antibody repertoire to FHbp epitopes outside of the FH-binding site, which did not inhibit FH binding [12] . For unknown reasons, these anti-FHbp antibodies enhanced FH binding [12] . In contrast, mutant FHbp vaccines with decreased FH binding elicited higher serum bactericidal activity in transgenic mice than control FHbp vaccines that bound human FH [11, 13, 32] . Further, the antibodies elicited by the mutant antigens inhibited binding of human FH to FHbp [11, 12] . Thus, failure of the mouse anti-FHbp antibodies elicited in the human FH transgenic mice to inhibit FH binding was specific for FHbp vaccine antigens that bound human FH [12] .
In the present study, we investigated the effect of binding of rhesus macaque FH on the immunogenicity of 4CMenB. In previous studies, C3b covalently bound to IgG was resistant to degradation by FH [33] . Further, both the amount of C3b and the location where C3b is deposited on the bacterial surface in the presence of bound antibody can affect bactericidal activity [33, 34] . Note also that the ability of anti-FHbp antibodies to inhibit or enhance FH binding was best detected at low human FH concentrations (2 µg/mL). However, typical human serum FH concentrations are approximately 150-500 µg/mL [11] . Under high physiologic serum FH concentrations, the anti-FHbp antibody-induced enhancement of FH binding may not result in functional differences in FH downregulation because FH binding to FHbp is saturated. In a previous study, saturation of FH binding to the bacterial surface explained why isogenic meningococcal mutants with FHbp sequences that differed by >10-fold in binding affinity to FH survived equally well in human plasma or whole blood from nonimmune donors [35] . In the present study, saturation of human FH binding also would explain why the mixing experiment to equalize ma- Thus, in this primate model, which is likely to be more relevant for predicting human antibody responses than mouse models, stronger binding of a primate host protein, FH, to a vaccine antigen decreased protective anti-FHbp antibody responses. Conceivably, mutant FHbp antigens with low FH binding may be superior immunogens in humans, compared with FHbp antigens that bind FH, and the mutants also may avoid the theoretical safety risk of eliciting autoreactive antibodies to FH [12] . However, given the desirability to elicit serum anti-FHbp antibodies that inhibit FH binding, it may be necessary to design mutant FHbp vaccines that completely eliminate FH binding in order for the antibody repertoire to be directed to FHbp epitopes in the FH-binding site.
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